These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 35570989)

  • 21. Does SGLT2 inhibition with dapagliflozin overcome individual therapy resistance to RAAS inhibition?
    Petrykiv S; Laverman GD; de Zeeuw D; Heerspink HJL
    Diabetes Obes Metab; 2018 Jan; 20(1):224-227. PubMed ID: 28685934
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Interaction Between the Sodium-Glucose-Linked Transporter 2 Inhibitor Dapagliflozin and the Loop Diuretic Bumetanide in Normal Human Subjects.
    Wilcox CS; Shen W; Boulton DW; Leslie BR; Griffen SC
    J Am Heart Assoc; 2018 Feb; 7(4):. PubMed ID: 29440005
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Renal Handling of Ketones in Response to Sodium-Glucose Cotransporter 2 Inhibition in Patients With Type 2 Diabetes.
    Ferrannini E; Baldi S; Frascerra S; Astiarraga B; Barsotti E; Clerico A; Muscelli E
    Diabetes Care; 2017 Jun; 40(6):771-776. PubMed ID: 28325783
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Dapagliflozin a glucose-regulating drug with diuretic properties in subjects with type 2 diabetes.
    Lambers Heerspink HJ; de Zeeuw D; Wie L; Leslie B; List J
    Diabetes Obes Metab; 2013 Sep; 15(9):853-62. PubMed ID: 23668478
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Albuminuria-lowering effect of dapagliflozin alone and in combination with saxagliptin and effect of dapagliflozin and saxagliptin on glycaemic control in patients with type 2 diabetes and chronic kidney disease (DELIGHT): a randomised, double-blind, placebo-controlled trial.
    Pollock C; Stefánsson B; Reyner D; Rossing P; Sjöström CD; Wheeler DC; Langkilde AM; Heerspink HJL
    Lancet Diabetes Endocrinol; 2019 Jun; 7(6):429-441. PubMed ID: 30992195
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Rationale and protocol of the Dapagliflozin And Prevention of Adverse outcomes in Chronic Kidney Disease (DAPA-CKD) randomized controlled trial.
    Heerspink HJL; Stefansson BV; Chertow GM; Correa-Rotter R; Greene T; Hou FF; Lindberg M; McMurray J; Rossing P; Toto R; Langkilde AM; Wheeler DC;
    Nephrol Dial Transplant; 2020 Feb; 35(2):274-282. PubMed ID: 32030417
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effects of the sodium-glucose cotransporter 2 inhibitor dapagliflozin on fluid distribution: A comparison study with furosemide and tolvaptan.
    Ohara K; Masuda T; Murakami T; Imai T; Yoshizawa H; Nakagawa S; Okada M; Miki A; Myoga A; Sugase T; Sekiguchi C; Miyazawa Y; Maeshima A; Akimoto T; Saito O; Muto S; Nagata D
    Nephrology (Carlton); 2019 Sep; 24(9):904-911. PubMed ID: 30578654
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Sodium glucose co-transporter 2 inhibitors and their mechanism for improving glycemia in patients with type 2 diabetes.
    Davidson JA; Kuritzky L
    Postgrad Med; 2014 Oct; 126(6):33-48. PubMed ID: 25414933
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Osmotic diuresis by SGLT2 inhibition stimulates vasopressin-induced water reabsorption to maintain body fluid volume.
    Masuda T; Muto S; Fukuda K; Watanabe M; Ohara K; Koepsell H; Vallon V; Nagata D
    Physiol Rep; 2020 Jan; 8(2):e14360. PubMed ID: 31994353
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The effects of dapagliflozin on cardio-renal risk factors in patients with type 2 diabetes with or without renin-angiotensin system inhibitor treatment: a post hoc analysis.
    Scholtes RA; van Raalte DH; Correa-Rotter R; Toto RD; Heerspink HJL; Cain V; Sjöström CD; Sartipy P; Stefánsson BV
    Diabetes Obes Metab; 2020 Apr; 22(4):549-556. PubMed ID: 31742881
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Effects of SGLT2 Inhibitors and GLP-1 Receptor Agonists on Renin-Angiotensin-Aldosterone System.
    Puglisi S; Rossini A; Poli R; Dughera F; Pia A; Terzolo M; Reimondo G
    Front Endocrinol (Lausanne); 2021; 12():738848. PubMed ID: 34745006
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effects of sodium-glucose cotransporter 2 inhibitors on urinary excretion of intact and total angiotensinogen in patients with type 2 diabetes.
    Yoshimoto T; Furuki T; Kobori H; Miyakawa M; Imachi H; Murao K; Nishiyama A
    J Investig Med; 2017 Oct; 65(7):1057-1061. PubMed ID: 28596160
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Sodium/glucose cotransporter 2 inhibitors and prevention of diabetic nephropathy: targeting the renal tubule in diabetes.
    De Nicola L; Gabbai FB; Liberti ME; Sagliocca A; Conte G; Minutolo R
    Am J Kidney Dis; 2014 Jul; 64(1):16-24. PubMed ID: 24673844
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Renal haemodynamic response to sodium-glucose cotransporter-2 inhibition does not depend on protein intake: An analysis of three randomized controlled trials.
    van der Aart-van der Beek AB; Cherney D; Laverman GD; Stefansson B; van Raalte DH; Hoogenberg K; Reyner D; Li Q; Di Tanna GL; Greasley PJ; Heerspink HJL
    Diabetes Obes Metab; 2021 Aug; 23(8):1961-1967. PubMed ID: 33908683
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Clinical pharmacokinetics and pharmacodynamics of dapagliflozin, a selective inhibitor of sodium-glucose co-transporter type 2.
    Kasichayanula S; Liu X; Lacreta F; Griffen SC; Boulton DW
    Clin Pharmacokinet; 2014 Jan; 53(1):17-27. PubMed ID: 24105299
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The dapagliflozin and prevention of adverse outcomes in chronic kidney disease (DAPA-CKD) trial: baseline characteristics.
    Wheeler DC; Stefansson BV; Batiushin M; Bilchenko O; Cherney DZI; Chertow GM; Douthat W; Dwyer JP; Escudero E; Pecoits-Filho R; Furuland H; Górriz JL; Greene T; Haller H; Hou FF; Kang SW; Isidto R; Khullar D; Mark PB; McMurray JJV; Kashihara N; Nowicki M; Persson F; Correa-Rotter R; Rossing P; Toto RD; Umanath K; Van Bui P; Wittmann I; Lindberg M; Sjöström CD; Langkilde AM; Heerspink HJL
    Nephrol Dial Transplant; 2020 Oct; 35(10):1700-1711. PubMed ID: 32862232
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Targeting renal glucose reabsorption to treat hyperglycaemia: the pleiotropic effects of SGLT2 inhibition.
    Vallon V; Thomson SC
    Diabetologia; 2017 Feb; 60(2):215-225. PubMed ID: 27878313
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Sodium Glucose Cotransporter 2 Inhibitors in the Treatment of Diabetes Mellitus: Cardiovascular and Kidney Effects, Potential Mechanisms, and Clinical Applications.
    Heerspink HJ; Perkins BA; Fitchett DH; Husain M; Cherney DZ
    Circulation; 2016 Sep; 134(10):752-72. PubMed ID: 27470878
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The effect of dapagliflozin on renal function in patients with type 2 diabetes.
    Kohan DE; Fioretto P; Johnsson K; Parikh S; Ptaszynska A; Ying L
    J Nephrol; 2016 Jun; 29(3):391-400. PubMed ID: 26894924
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Effect of exenatide twice daily and dapagliflozin, alone and in combination, on markers of kidney function in obese patients with type 2 diabetes: A prespecified secondary analysis of a randomized controlled clinical trial.
    van Ruiten CC; van der Aart-van der Beek AB; IJzerman RG; Nieuwdorp M; Hoogenberg K; van Raalte DH; Heerspink HJL
    Diabetes Obes Metab; 2021 Aug; 23(8):1851-1858. PubMed ID: 33908691
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.